Azmi Nabulsi - 19 Jan 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Chief Operating Officer
Signature
/s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi
Issuer symbol
PHAT
Transactions as of
19 Jan 2023
Transactions value $
$0
Form type
4
Filing time
20 Jan 2023, 18:35:40 UTC
Previous filing
02 Sep 2022
Next filing
11 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +45K +100.97% $0.00 89.6K 19 Jan 2023 Direct F1, F2
holding PHAT Common Stock 2.36K 19 Jan 2023 by 401(k)
holding PHAT Common Stock 786K 19 Jan 2023 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option (Right to Buy) Award $0 +75K $0.00 75K 19 Jan 2023 Common Stock 75K $8.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 2,596 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.
F3 The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.